Live feed06:00:00·999dPRReleasevia QuantisnowImmunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsByQuantisnow·Wall Street's wire, on your screen.IMVT· Immunovant Inc.Health Care
